This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Endo International plc
Drug Names(s): PW2101
Description: PW2101 is a beta blocker intended for the treatment of hypertension and angina.
Deal Structure: In August 2010, Penwest Pharmaceuticals announced that it has entered into a merger agreement under which Endo Pharmaceuticals has agreed to acquire all of the common stock of Penwest for $5.00 per share in cash. The acquisition was completed in November 2010.
Pink Sheet Penwest drops "not approvable" beta blocker
Additional information available to subscribers only: